Skip to main content

Sullivan Timothy Eugene's Form 4 filing

Apellis Pharmaceuticals, Inc.APLS · filed Sep 10, 2025

Accession no.
0001127602-25-021248
Filed
Sep 10, 2025
Trade date
Sep 8, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.19M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sullivan Timothy EugeneCIK 0001707000Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 8, 2025Common StockMOption exerciseAcquired+15,000$10.03+$150,450143,665Direct
Sep 8, 2025Common StockSSaleDisposed−32,729$27.86−$911,829.94110,936Direct
Sep 8, 2025Common StockSSaleDisposed−10,000$27.83F2−$278,30060,396Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 8, 2025Common StockMOption exerciseDisposed−15,000$0.00$0242,903Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.98, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)